Meetings

Scientific Program for the 2022 ASH Summit on Emerging Immunotherapies

Keynote Address

Thursday, March 24, 2022: 8:15 AM - 9:00 AM

Chair:

Shannon L. Maude, MD, PhD, Children's Hospital of Philadelphia, Philadelphia, PA

Speaker:

 Stanley R. Riddell, MD, Fred Hutchinson Cancer Research Center, Seattle, WA

The Science of Immunotherapy

Thursday, March 24, 2022: 9:00 AM - 10:45 AM

Co-Chairs:

  • Antonio Risitano, MD, PhD, University of Naples, Naples, Italy
  • Madhav V Dhodapkar, MD, Emory University, Atlanta, GA

Speakers:

  • Ira Mellman, PhD, Genentech, New Haven, CT
    The Future of Science of Cancer Immunotherapy.
  • Padmanee Sharma, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX
    Mechanisms of Innate and Adaptive Resistance
  • Phillip Scheinberg, MD, Division of Hematology, Hospital A Beneficência Portuguesa, Sao Paulo, MT, Brazil
    Uncertain Mechanisms of Action of Successful Biologics - ATG Focus

Use of Immunotherapies in Clinical Practice or Trials

Thursday, March 24, 2022: 10:55 AM - 12:00 PM

Co-Chairs:

  • Katayoun Rezvani, MD, PHD, MD Anderson Cancer Center, Houston, TX
  • Sarah Cooley, MD, University of Minnesota, Minneapolis, MN

Speakers:

  • Dean Anthony Lee, MD, PhD, The Research Institute At Nationwide Children’s Hospital, Columbus, OH
    Chimeric Antigen Receptor (CAR) Engineering Beyond T-Cells
  • Aude G. Chapuis, MD, Fred Hutchinson Cancer Research Center, Seattle, WA
    T-Cell Engineering Beyond CAR

Use of Immunotherapies in Clinical Practice or Trials (Cont’d)

Thursday, March 24, 2022: 1:00 PM - 2:30 PM

Co-Chairs:

  • Sarah Cooley, MD, University of Minnesota, Minneapolis, MN
  • Katayoun Rezvani, MD, PHD, MD Anderson Cancer Center, Houston, TX

Speakers:

  • Stacy E. Croteau, MD, Children's Hospital Boston, Boston, MA
    Bispecific Antibodies in Hemophilia
  • Chengcheng Fu, MD, PhD
    Presentation from the Chinese Society of Hematology: BCMA CART in China and Beyond

Mechanisms of Resistance to Immunotherapies

Thursday, March 24, 2022: 2:30 PM - 4:15 PM

Co-Chairs:

  • Rodrigo T. Calado, MD, PhD, University of Sao Paulo, Ribeirão Preto, SP, Brazil
  • Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:

  • Nirali N. Shah, MD, National Cancer Institute/NIH, Bethesda, MD
    Relapse Associated with Late Immunotherapy Failure
  • Eleni Gavriilaki, MD, PhD, George Papanicolaou General Hospital, Thessaloniki, Greece
    Targeting Innate Immunity: Anti-Complement Therapies

Cell Manufacturing Considerations: Transitioning from Early to Late Phase Trials to Licensure

Thursday, March 24, 2022: 4:55 PM - 6:40 PM

Co-Chairs:

  • Catherine M. Bollard, MD, MBChB, Children's National Hospital and The George Washington University, Washington, DC
  • Terry J. Fry, MD, Sana Biotechnology/University of Colorado, Denver, CO

Speakers:

Isabelle Rivière, PhD, Memorial Sloan Kettering Cancer Center, New York, NY
Academia Perspective: Challenges in the Academia Setting to Take Novel Platforms into the Clinic - How Have They Approached IND Filings (gene editing) 

Emerging Strategies to Overcome Current Immunotherapy Limitations

Friday, March 25, 2022: 8:00 AM - 9:45 AM

Co-Chairs:

  • David W. Scott, PhD, Uniformed Services University of Health Sciences, Bethesda, MD
  • Frederick L. Locke, MD, Moffitt Cancer Center, Tampa, FL

Speakers:

  • Marcela V. Maus, MD, Massachusetts General Hospital, Harvard Medical School, Lexington, MA
    Improving CAR T By Promoting Intracellular and Extracellular Signaling
  • Shannon Meeks, MD, Emory University, Atlanta, GA
    Emicizumab and ITI: Partners or Foes
  • Chiara Bonini, MD, OSPEDALE SAN RAFFAELE, Milano, Italy
    Off the Shelf CARs

Immunotherapy Toxicities – Prediction and Management

Friday, March 25, 2022: 11:45 AM - 1:30 PM

Co-Chairs:

  • Jae H Park, MD, Memorial Sloan-Kettering Cancer Ctr., New York, NY
  • Rayne H. Rouce, MD , Clinical Care Center-Texas Children's Hospital, Houston, TX

Speakers:

  • David T. Teachey, MD, Children's Hospital of Philadelphia, Rutledge, PA
    Cytokine Release Syndrome
  • Juliane Gust, MD, PhD, Seattle Children's, Seattle, WA
    Neurotoxicity
  • Elad Sharon, MD, MPH, Cancer Therapy Evaluation Program, Bethesda, MD
    Off-Target Effects of Immunotherapy

Late Breaking Special Session (ASH-SITC JOINT Session)

Friday, March 25, 2022: 2:30 PM - 4:00 PM

This session will be developed at a later date in collaboration with the Society for Immunotherapy of Cancer (SITC)